<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
OLMA
Olema Oncology
$
()


  • Olema Oncology price target raised by $9 at Oppenheimer, here's why

    6/4/2024 - 14:10pm
  • Olema Oncology announces new data on palazestrant with ribociclib

    5/15/2024 - 07:23am
  • Olema Oncology reports Q1 EPS (56c), consensus (55c)

    5/8/2024 - 16:25pm
  • Olema Oncology to present clinical data for palazestrant combination at ESMO

    5/8/2024 - 07:28am
  • Citi opens 'positive catalyst watch' on Olema Oncology into data

    5/2/2024 - 06:01am
  • Olema Oncology initiated with bullish view at Goldman Sachs, here's why

    4/2/2024 - 04:57am
  • Olema Oncology reports Q4 EPS (49c), consensus (48c)

    3/11/2024 - 16:06pm
  • Olema Oncology announces publication of data on palazestrant

    3/6/2024 - 07:09am
  • Olema Oncology files to sell 13.21M shares of common stock for holders

    1/31/2024 - 16:24pm
  • Olema Oncology initiated with bullish view at Citi, here's why

    1/30/2024 - 05:04am
  • Olema Oncology nominates OP-3136 as development candidate

    1/8/2024 - 08:37am
  • Olema Oncology announces interim results from Phase 1b/2 study of palazestrant

    12/5/2023 - 12:30pm
  • Olema Oncology to present new Palazestrant clinical data at SABCS

    11/28/2023 - 17:19pm
  • Olema Oncology price target lowered to $28 from $29 at JPMorgan

    11/22/2023 - 06:08am
  • Olema Oncology reports Q3 EPS (48c), consensus (51c)

    11/7/2023 - 16:34pm
dynamic_feed Breaking News